Anti-Coagulants - Iraq

Iraq

In Iraq, the Anti-Coagulants market is anticipated to witness a significant increase in revenue, with projections indicating it will reach US$37.03m in 2024.
Furthermore, the market is expected to exhibit a steady annual growth rate (CAGR 2024-2029) of 7.70%, leading to a market volume of US$53.65m by 2029.
When compared to other countries worldwide, United States is predicted to generate the highest revenue in this market, amounting to US$16,740.00m in 2024.
Despite the challenges faced by Iraq's healthcare system, the demand for anti-coagulants is steadily rising due to an aging population.

Key regions: Australia, Japan, United States, Germany, Europe

Market

Region

Region comparison

Currency

Analyst Opinion

The Anti-Coagulants market in Iraq has been steadily growing in recent years.

Customer preferences: Iraq has a high prevalence of cardiovascular diseases, which has led to an increasing demand for Anti-Coagulants. Additionally, the aging population in the country has also contributed to the growth of the market.

Trends in the market: The Anti-Coagulants market in Iraq is dominated by the oral anticoagulant segment, which is expected to continue to grow in the coming years. This can be attributed to the convenience and ease of use of oral medications. However, the injectable segment is also expected to grow due to the need for acute care in hospitals. The market is also seeing an increase in the use of direct oral anticoagulants (DOACs), which are becoming more popular due to their efficacy and safety.

Local special circumstances: One of the challenges in the Anti-Coagulants market in Iraq is the lack of awareness among patients and healthcare professionals about the benefits of anticoagulant therapy. This has led to a low diagnosis rate and underutilization of anticoagulants. Additionally, the healthcare system in Iraq faces several challenges, including a shortage of healthcare professionals and inadequate infrastructure.

Underlying macroeconomic factors: Iraq has a growing economy, which has led to an increase in healthcare spending. The government has also taken steps to improve the healthcare system in the country, which is expected to drive the growth of the Anti-Coagulants market. However, the political instability and security situation in the country pose a risk to the market's growth.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.